Protocol Ledger

NCT04401748 · Phase III · ACTIVE NOT RECRUITING

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Interventional Phase III clinical trial protocol NCT04401748 sponsored by AbbVie in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-10 Enrollment: 531 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04401748
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)531 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04401748
Protocol FieldVerified Registry Value
NCT IdentifierNCT04401748
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment531 participants (ACTUAL)
Registered Start Date2020-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI